SavedAdd your journal

Journals / Hacettepe Üniversitesi Eczacılık Fakültesi Dergisi / 2022 / Cilt: 42 - Sayı: 2

Design, Synthesis and Antimycobacterial Activity of 2-(Benzimidazol-2-yl)-propanenitrile Analogs

Oya Ünsal TAN
Mustafa Mert SIRIM
Siva Krishna VAGOLU
Sriram DHARMARAJAN
Pages
83–92
Publication Date
2022-06-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These results suggest that 4c may be a good candidate for drug development owing to potential against both active and dormant forms of M. tuberculosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:This paper reports the synthesis and evaluation of some new 2-(benzimidazol-2-yl)-3-(4-(4-substitutedpiperazin-1-yl)phenyl)propanenitrile derivatives for their in vitro antimycobacterial activities against Mycobacterium tuberculosis H37Rv.
📊
Key Findings & Data:Among them, 4c was found to be the most active compound with MIC of 1.56 μg/mL against M. tuberculosis.
💡
Conclusion & Impact:These results suggest that 4c may be a good candidate for drug development owing to potential against both active and dormant forms of M. tuberculosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:benzimidazol · propannitril · antimikobakteriyel aktivite

Abstract

This paper reports the synthesis and evaluation of some new 2-(benzimidazol-2-yl)-3-(4-(4-substitutedpiperazin-1-yl)phenyl)propanenitrile derivatives for their in vitro antimycobacterial activities against Mycobacterium tuberculosis H37Rv. Among them, 4c was found to be the most active compound with MIC of 1.56 μg/mL against M. tuberculosis. In addition, 4c showed 2.1 log reduction against nutrient starved M. tuberculosis which is more potent than first line drugs. Based on their predicted physicochemical values, the compounds obeyed the Lipinski’s "rule of five," and TPSA/nROT limits. Molecular docking studies were performed to estimate the orientation of 4c at the active site of M. tuberculosis LAT enzyme. These results suggest that 4c may be a good candidate for drug development owing to potential against both active and dormant forms of M. tuberculosis.

Özet

Bu makale, Mycobacterium tuberculosis H37Rv'ye karşı in vitro antimikobakteriyel aktiviteleri için bazı yeni 2-(benzimidazol-2-yl)-3-(4-(4-substitüepiperazin-1-yl)fenil)propannitril türevlerinin sentezini ve aktivitelerinin değerlendirilmesini içermektedir. Bileşikler arasında M. tuberculosis'e karşı 1.56 μg/mL MIC değeri ile en aktif bileşik 4c olarak bulundu. Ek olarak, 4c, besin açlık modeli testinde 2.1 log azalma sağlayarak birinci basamak ilaçlardan daha güçlü antimikobakteriyel aktivite göstermiştir. Hesaplanan fizikokimyasal değerlere dayanarak, bileşiklerin Lipinski'nin "beşler kuralına" ve TPSA/nROT limitlerine uyduğu tahmin edilmektedir. 4c'nin M. tuberculosis LAT enziminin aktif bölgesindeki oryantasyonunu tahmin etmek için moleküler yerleştirme çalışmaları yapıldı. Bu sonuçlar, M. tuberculosis'in hem aktif hem de latent formlarına karşı potansiyeli nedeniyle 4c'nin ilaç geliştirme için iyi bir aday olabileceğini düşündürmektedir.

🔖

Cite This Article

TAN, O. Ü., SIRIM, M. M., VAGOLU, S. K., DHARMARAJAN, S. (2022). Design, Synthesis and Antimycobacterial Activity of 2-(Benzimidazol-2-yl)-propanenitrile Analogs. Hacettepe Üniversitesi Eczacılık Fakültesi Dergisi, Cilt: 42 - Sayı: 2, 83–92. https://ajindex.com/articles/762251

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Dheda, K.; Barry, C. E.; Maartens, G. Tuberculosis. Lancet 2016, 387 (10024), 1211–1226. https://doi.org/10.1016/S0140-6736(15)00151-8. (2) Global Tuberculosis Report 2019; World Health Organization 2019, Ed.; 2019. (3) Gandhi, N. R.; Brust, J. C. M.; Shah, N. S. A New Era for Treatment of Drug-Resistant Tuberculosis. Eur. Respir. J. 2018, 52, 1801350. https://doi.org/10.1183/13993003.01350-2018. (4) Nahid, P.; Mase, S. R.; Migliori, G. B.; Sotgiu, G.; Bothamley, G. H.; Brozek, J. L. et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2019, 200 (10), e93–e142. https://doi.org/10.1164/rccm.201909-1874ST. (5) Blumberg, H. M.; Ernst, J. D. The Challenge of Latent TB Infection. JAMA 2016, 316 (9), 931–933. https://doi.org/10.1001/jama.2016.11021. (6) van den Boogaard, J.; Kibiki, G. S.; Kisanga, E. R.; Boeree, M. J.; Aarnoutse, R. E. New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development. Antimicrob. Agents Chemother. 2009, 53 (3), 849 LP – 862. https://doi.org/10.1128/AAC.00749-08. (7) Tiberi, S.; Muñoz-Torrico, M.; Duarte, R.; Dalcolmo, M.; D’Ambrosio, L.; Migliori, G.-B. New Drugs and Perspectives for New Anti-Tuberculosis Regimens. Pulmonology 2018, 24 (2), 86–98. https://doi.org/10.1016/j.rppnen.2017.10.009. (8) Akhtar, W.; Khan, M. F.; Verma, G.; Shaquiquzzaman, M.; Rizvi, M. A.; Mehdi, S. H.; Akhter, M.; Alam, M. M. Therapeutic Evolution of Benzimidazole Derivatives in the Last Quinquennial Period. Eur. J. Med. Chem. 2017, 126, 705–753. https://doi.org/https://doi.org/10.1016/j.ejmech.2016.12.010. (9) Keri, R. S.; Hiremathad, A.; Budagumpi, S.; Nagaraja, B. M. Comprehensive Review in Current Developments of Benzimidazole-Based Medicinal Chemistry. Chem. Biol. Drug Des. 2015, 86 (1), 19–65. https://doi.org/10.1111/cbdd.12462. (10) Surineni, G.; Gao, Y.; Hussain, M.; Liu, Z.; Lu, Z.; Chhotaray, C.; Islam, M. M.; Hameed, H. M. A.; Zhang, T. Design, Synthesis, and in Vitro Biological Evaluation of Novel Benzimidazole Tethered Allylidenehydrazinylmethylthiazole Derivatives as Potent Inhibitors of Mycobacterium Tuberculosis. Medchemcomm 2019, 10 (1), 49–60. https://doi.org/10.1039/C8MD00389K. (11) Chandrasekera, N. S.; Berube, B. J.; Shetye, G.; Chettiar, S.; O’Malley, T.; Manning, A.; Flint, L.; Awasthi, D.; Ioerger, T. R.; Sacchettini, J.; Masquelin, T.; Hipskind, P. A.; Odingo, J.; Parish, T. Improved Phenoxyalkylbenzimida